MANE

Veradermics Inc

Feb 05 • 04:00PM ET

37.16

-0.59 -1.56 %

Healthcare • Biotechnology • USA • NYSE

Feb 05, 4:12 PMVeradermics announces closing of its upsized IPO at $17 per share with underwriters fully exercising the option, bringing the total offering to 17.34 million shares and gross proceeds to approximately $294.8 million.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	35.08M	Perf Week	-
Market Cap	1.30B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	1.35B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-1.56%
Book/sh	-1.38	P/C	24.56	EPS next 5Y	-	ROE	-	52W High	40.01 -7.12%	Perf Year	-
Cash/sh	1.51	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	32.00 16.12%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	6.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	11.77	EPS Q/Q	-	SMA20	-0.79%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-0.79%	Rel Volume	0.28	Prev Close	37.75
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-0.79%	Avg Volume	3.32M	Price	37.16
IPO	Feb 04, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	933,766	Change	-1.56%

Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MANE

Veradermics Inc

Upgrade your FINVIZ experience